LexDanaLexDanabeta
Inventor

Aranapakam M. Venkatesan

Inventor
Rego Park, NY, US

Overview

61→
Patents
1994–2019
Patent span
Chemistry
Primary field (CPC C)

Patents· 61 as inventor

Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.

C07Dprimary
C07DHeterocyclic compounds44%
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations22%
A61KPreparations for medical, dental or toiletry purposes20%
C07CAcyclic or carbocyclic compounds8%
C07FAcyclic, carbocyclic or heterocyclic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur, selenium or tellurium2%
C12QMeasuring or testing processes involving enzymes, nucleic acids or microorganisms1%
G01NInvestigating or analysing materials by determining their chemical or physical properties1%
Y02ATechnologies for adaptation to climate change1%
PatentTitleYear
10,294,212Inhibitors of the kynurenine pathway201910,022,381Triazine compounds as PI3 kinase and mTOR inhibitors20189,815,811'Inhibitors of the kynurenine pathway'20179,174,963'Triazine compounds as PI3 kinase and MTOR inhibitors'20158,859,542'Triazine compounds as PI3 kinase and mTOR inhibitors'20148,748,421'Triazine compounds as P13 kinase and MTOR inhibitors'20148,575,159'Triazine compounds as PI3 kinase and mTOR inhibitors'20138,445,486'Triazine compounds as PI3 kinase and mTOR inhibitors'20138,217,036'Triazine compounds as PI3 kinase and mTOR inhibitors'20128,039,469'Triazine compounds as PI3 kinase and mTOR inhibitors'20117,812,014'Bicyclic 6-alkylidene-penems as β-lactamase inhibitors'20107,691,842'Tricyclic 6-alkylidene-penems as β-lactamase inhibitors'20107,332,506'Substituted-3-indolyl-4-piperidino-alkyl heterocycles for the treatment of depression'20087,276,611'Process for synthesizing beta-lactamase inhibitor intermediates'20077,276,603'Benzofuranyl-and benzothienyl-piperazinyl quinolines and methods of their use'20077,235,569'Piperidinyl indole and tetrohydropyridinyl indole derivatives and method of their use'20077,229,983'4-substituted or unsubstituted-7-hydro-1,4-thiazepine-7-[bicyclic or tricyclic heteroaryl] substituted-3,6-dicarboxylic acid derivatives as β-lactamase inhibitors'20077,148,235'Substituted-3-indolyl-4-piperidino-alkyl heterocycles for the treatment of depression'20067,112,582'Bicyclic 6-alkylidene-penems as β-lactamase inhibitors'20067,018,997'Tricyclic 6-alkylidene-penems as β-lactamase inhibitors'20066,939,870'Substituted-3-indolyl-4-piperidino-alkyl heterocycles for the treatment of depression'20056,825,354'Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase and TACE inhibitors'20046,753,337'Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase/tace inhibitors'20046,462,073'N-hydroxy-2-(alkyl, aryl, or heteroaryl sulfanyl, sulfinyl or sulfonyl)-3-substituted alkyl, aryl or heteroarylamides as matrix metalloproteinase inhibitors'20026,444,704'N-hydroxy-2-(alkyl, aryl, or heteroaryl sulfanyl, sulfinyl or sulfonyl)-3-substituted alkyl, aryl or heteroarylamides as matrix metalloproteinase inhibitors'20026,441,023'N-hydroxy-2-(alkyl, aryl, or heteroaryl sulfanyl, sulfinyl or sulfonyl)-3-substituted alkyl, aryl or heteroarylamides as matrix metalloproteinase inhibitors'20026,358,980'Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase/tace inhibitors'20026,342,508'N-hydroxy-2-(Alkyl,Aryl or Heteroaryl sulfanyl, sulfinyl or sulfonyl) 3-substituted alkyl, aryl or heteroarylamides as matrix metalloproteinase inhibitors'20026,340,691'Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase and tace inhibitors'20026,331,563'N-Hydroxy-2-(Alkyl, Aryl, or Heteroaryl, Sulfanyl, Sulfinyl or Sulfonyl)-3-Substituted Alkyl, Aryl or Heteroarylamides as Matrix Metalloproteinase inhibitors'20016,288,086'N-hydroxy-2-(alkyl, aryl, or heteroaryl, sulfanyl, sulfinyl or sulfonyl)-3-substituted alkyl, aryl or heteroarylamides as matrix metalloproteinase inhibitors'20016,197,791'N-hdroxy-2-(alkyl, aryl, or heteroaryl, sulfanyl, sulfinyl or sulfonyl)-3-substituted alkyl, aryl or heteroarylamides as matrix metalloproteinase inhibitors'20016,172,057'N-Hydroxy-2-(alkyl, aryl, or heteroaryl sulfanyl, sulfinyl or sulfonyl)-3-substituted alkyl, aryl or heteroarylamides as matrix metalloproteinase inhibitors'20016,083,975'Substituted benzo[1,4]dioxines as antiobesity agents'20006,020,361'Substituted benzo[1,4]dioxines as antiobesity agents'20005,965,607'Substituted Benzo[1,4]dioxines as antiobesity agents'19995,929,097'Preparation and use of ortho-sulfonamido aryl hydroxamic acids as matrix metalloproteinase and tace inhibitors'19995,914,339'Substituted 1,3-benzodioxoles'19995,849,735'Tricyclic benzazepine vasopressin antagonists'19985,780,471'Tricyclic benzazepine vasopressin antagonists'19985,753,648'Tricyclic benzazepine vasopressin antagonists'19985,700,796'Tricyclic benzazepine vasopressin antagonists'19975,610,156'Tricyclic benzazepine vasopressin antagonists'19975,594,152'Process for the preparation of tricyclic-heterocycles'19975,536,718'Tricyclic benzazepine vasopressin antagonists'19965,532,235'Tricyclic benzazepine vasopressin antagonists'19965,521,173'Tricyclic benzazepine vasopressin antagonists'19965,436,333'Process for the preparation of tricyclic-heterocycles'19955,405,849'Angiotensin II receptor blocking 2,3,6 substituted quinazolinones'19955,358,951'Angiotensin II receptor blocking 2, 3, 6 substituted quinazolinones'19945,358,947'Angiotensin II receptor blocking 2,3-substituted pyrazolo[1,5-a]-1,3,5-triazin-4(3H)-ones'19945,294,611'Angiotensin II receptor blocking 2,3,6 substituted quinazolinones'19945,294,617'Angiotensin II receptor blocking 2,3,6 substituted quinazolinones'19945,292,734'Angiotensin II receptor blocking 2,3,6 substituted quinazolinones'19945,292,742'Angiotensin II receptor blocking 2,3,6 substituted quinazolinones'19945,290,780'Angiotensin II receptor blocking 2,3,6 substituted quinazolinones'19945,286,729'Angiotensin II receptor blocking 2,3,6 substituted quinazolinones'19945,284,853'Angiotensin II receptor blocking 2,3,6 substituted quinazolinones'19945,284,852'Angiotensin II receptor blocking 2,3,6-substituted quinazolinones'19945,281,604'Angiotensin II receptor blocking 2,3,6-substituted quinazolinones'19945,281,603'Angiotensin II receptor blocking 2,3,6 substituted quinazolinones'1994

Career & activity timeline

Assembled from patent assignee/location history and declaration credentials.

1994–2002Patents assigned to AMERICAN CYANAMID CO (31)· patent assignee history
1994–1998Based in Elmhurst, NY, US· patent location history
1995–2019Based in Rego Park, NY, US· patent location history
1996–2002Patents assigned to AMERICAN HOME PROD (5)· patent assignee history
1998Based in Queens County, NY, US· patent location history
2002–2004Based in Cliffton Park, NY, US· patent location history
2004–2008Patents assigned to WYETH CORP (11)· patent assignee history
2007Based in Regopark, NY, US· patent location history
2010–2018Patents assigned to WYETH LLC (10)· patent assignee history
2013–2018Patents assigned to PFIZER (3)· patent assignee history

Inventor activity

Assignee and location history derived from the patent record.

Assignees
AssigneePatentsSpan
AMERICAN CYANAMID CO311994–2002
WYETH CORP112004–2008
WYETH LLC102010–2018
AMERICAN HOME PROD51996–2002
PFIZER32013–2018
Locations
LocationPatentsSpan
Rego Park, New York, US351995–2019
Elmhurst, New York, US201994–1998
Regopark, New York, US22007
Cliffton Park, New York, US22002–2004
Queens County, New York, US11998